Drug details

Asparlas (calaspargase pegol-mknl injection)

type of Enzymes, Oncology

Asparlas (calaspargase pegol - mknl) is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.

This drug may have the following side effects:

• diarrhea,
• shortness of breath,
• bleeding,
• elevated transaminase,
• bilirubin increased,
• pancreatitis,
• abnormal clotting studies,
• hypersensitivity,
• pneumonia, and
• abnormal heart rate

The following drugs are related to Asparlas, either as a replacement or used together:

• Scemblix (asciminib tablets)
• Rylaze (asparaginase erwinia chrysanthemi (recombinant) - rywn) injection)
• Belrapzo (bendamustine hydrochloride injection)
• Bosulif (bosutinib tablets)
• Cytoxan (cyclophosphamide)
• Cytarabine (cytarabine)
• Doxorubicin Hydrochloride Injection (doxorubicin hydrochloride injection)
• Gleevec (imatinib mesylate)
• Tasigna Capsules (nilotinib capsules)
• Prednisone (prednisone tablets, usp)
• Rituxan (rituximab)
• Rituxan Hycela (rituximab and hyaluronidase human injection)